We are live on ! Find out more
VRX

VALEANT PHARMACEUTICALS INTL
VRX

Delisted

VRX was delisted on the 27th of September, 2010.

Back to rankings

2 hedge funds and large institutions have $546K invested in VALEANT PHARMACEUTICALS INTL in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more capital invested

Capital invested by funds: $339K → $546K (+$207K)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBI
Baxter Bros Inc
Connecticut
+$15.1K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BBI
1
Baxter Bros Inc
Connecticut
$545K +$15.1K +875 +3%
SIM
2
Sonora Investment Management
Arizona
$1.04K – – –

VRX Hedge Fund Activity: Q2 2017 in Review

2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q2 2017, worth a combined $546K — up 61% from $339K a quarter earlier.

Fund positioning in VRX was balanced in Q2 2017: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Baxter Bros Inc, adding an estimated $15.1K.

  • 2 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $546K of VALEANT PHARMACEUTICALS INTL stock for Q2 2017, up 61% quarter-over-quarter.
  • 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q2 2017 and 0 closed out.
  • The largest VALEANT PHARMACEUTICALS INTL buyer in Q2 2017 was Baxter Bros Inc, an estimated $15.1K added.

Based on aggregated 13F filings for Q2 2017.